Abstract
Different methods for detecting circulating tumour cells (CTCs) in the blood of patients with cancer yield distinct results with regard to cell counts and CTC subpopulations. This observation underlines the urgent need for comprehensive standardization and validation of novel CTC technologies in order to facilitate their introduction into clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.